Diarmaid Hughes1, Conor Judge1,2,3, Robert Murphy1, Elaine Loughlin1, Maria Costello1, William Whiteley4, Jackie Bosch5, Martin J O'Donnell1,5, Michelle Canavan1. 1. HRB Clinical Research Facility, NUI Galway and Saolta University Hospital Group, Galway, Ireland. 2. Translational Medical Device Lab, NUI Galway, Galway, Ireland. 3. Wellcome Trust-HRB, Irish Clinical Academic Training, Dublin, Ireland. 4. Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, Scotland. 5. Population Health Research Institute, Hamilton, Canada.
Abstract
Importance: The benefit of blood pressure lowering for the prevention of dementia or cognitive impairment is unclear. Objective: To determine the association of blood pressure lowering with dementia or cognitive impairment. Data Sources and Study Selection: Search of PubMed, EMBASE, and CENTRAL for randomized clinical trials published from database inception through December 31, 2019, that evaluated the association of blood pressure lowering on cognitive outcomes. The control groups consisted of either placebo, alternative antihypertensive agents, or higher blood pressure targets. Data Extraction and Synthesis: Data were screened and extracted independently by 2 authors. Random-effects meta-analysis models were used to report pooled treatment effects and CIs. Main Outcomes and Measures: The primary outcome was dementia or cognitive impairment. The secondary outcomes were cognitive decline and changes in cognitive test scores. Results: Fourteen randomized clinical trials were eligible for inclusion (96 158 participants), of which 12 reported the incidence of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-up and were included in the primary meta-analysis, 8 reported cognitive decline, and 8 reported changes in cognitive test scores. The mean (SD) age of trial participants was 69 (5.4) years and 40 617 (42.2%) were women. The mean systolic baseline blood pressure was 154 (14.9) mm Hg and the mean diastolic blood pressure was 83.3 (9.9) mm Hg. The mean duration of follow-up was 49.2 months. Blood pressure lowering with antihypertensive agents compared with control was significantly associated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 participants) (7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years; odds ratio [OR], 0.93 [95% CI, 0.88-0.98]; absolute risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21.1% of participants over a mean trial follow-up of 4.1 years; OR, 0.93 [95% CI, 0.88-0.99]; absolute risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%). Blood pressure lowering was not significantly associated with a change in cognitive test scores. Conclusions and Relevance: In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents compared with control was significantly associated with a lower risk of incident dementia or cognitive impairment.
Importance: The benefit of blood pressure lowering for the prevention of dementia or cognitive impairment is unclear. Objective: To determine the association of blood pressure lowering with dementia or cognitive impairment. Data Sources and Study Selection: Search of PubMed, EMBASE, and CENTRAL for randomized clinical trials published from database inception through December 31, 2019, that evaluated the association of blood pressure lowering on cognitive outcomes. The control groups consisted of either placebo, alternative antihypertensive agents, or higher blood pressure targets. Data Extraction and Synthesis: Data were screened and extracted independently by 2 authors. Random-effects meta-analysis models were used to report pooled treatment effects and CIs. Main Outcomes and Measures: The primary outcome was dementia or cognitive impairment. The secondary outcomes were cognitive decline and changes in cognitive test scores. Results: Fourteen randomized clinical trials were eligible for inclusion (96 158 participants), of which 12 reported the incidence of dementia (or composite of dementia and cognitive impairment [3 trials]) on follow-up and were included in the primary meta-analysis, 8 reported cognitive decline, and 8 reported changes in cognitive test scores. The mean (SD) age of trial participants was 69 (5.4) years and 40 617 (42.2%) were women. The mean systolic baseline blood pressure was 154 (14.9) mm Hg and the mean diastolic blood pressure was 83.3 (9.9) mm Hg. The mean duration of follow-up was 49.2 months. Blood pressure lowering with antihypertensive agents compared with control was significantly associated with a reduced risk of dementia or cognitive impairment (12 trials; 92 135 participants) (7.0% vs 7.5% of patients over a mean trial follow-up of 4.1 years; odds ratio [OR], 0.93 [95% CI, 0.88-0.98]; absolute risk reduction, 0.39% [95% CI, 0.09%-0.68%]; I2 = 0.0%) and cognitive decline (8 trials) (20.2% vs 21.1% of participants over a mean trial follow-up of 4.1 years; OR, 0.93 [95% CI, 0.88-0.99]; absolute risk reduction, 0.71% [95% CI, 0.19%-1.2%]; I2 = 36.1%). Blood pressure lowering was not significantly associated with a change in cognitive test scores. Conclusions and Relevance: In this meta-analysis of randomized clinical trials, blood pressure lowering with antihypertensive agents compared with control was significantly associated with a lower risk of incident dementia or cognitive impairment.
Authors: Tessa van Middelaar; Lonneke A van Vught; Willem A van Gool; Esther M F Simons; Bert-Jan H van den Born; Eric P Moll van Charante; Edo Richard Journal: J Hypertens Date: 2018-09 Impact factor: 4.844
Authors: Françoise Forette; Marie-Laure Seux; Jan A Staessen; Lutgarde Thijs; Marija-Ruta Babarskiene; Speranta Babeanu; Alfredo Bossini; Robert Fagard; Blas Gil-Extremera; Tovio Laks; Zhanna Kobalava; Cinzia Sarti; Jaakko Tuomilehto; Hannu Vanhanen; John Webster; Yair Yodfat; Willem H Birkenhäger Journal: Arch Intern Med Date: 2002-10-14
Authors: W B Applegate; S Pressel; J Wittes; J Luhr; R B Shekelle; G H Camel; M R Greenlick; E Hadley; L Moye; H M Perry Journal: Arch Intern Med Date: 1994-10-10
Authors: B E de Galan; S Zoungas; J Chalmers; C Anderson; C Dufouil; A Pillai; M Cooper; D E Grobbee; M Hackett; P Hamet; S R Heller; L Lisheng; S MacMahon; G Mancia; B Neal; C Y Pan; A Patel; N Poulter; F Travert; M Woodward Journal: Diabetologia Date: 2009-08-18 Impact factor: 10.122
Authors: Ilya M Nasrallah; Nicholas M Pajewski; Alexander P Auchus; Gordon Chelune; Alfred K Cheung; Maryjo L Cleveland; Laura H Coker; Michael G Crowe; William C Cushman; Jeffrey A Cutler; Christos Davatzikos; Lisa Desiderio; Jimit Doshi; Guray Erus; Larry J Fine; Sarah A Gaussoin; Darrin Harris; Karen C Johnson; Paul L Kimmel; Manjula Kurella Tamura; Lenore J Launer; Alan J Lerner; Cora E Lewis; Jennifer Martindale-Adams; Claudia S Moy; Linda O Nichols; Suzanne Oparil; Paula K Ogrocki; Mahboob Rahman; Stephen R Rapp; David M Reboussin; Michael V Rocco; Bonnie C Sachs; Kaycee M Sink; Carolyn H Still; Mark A Supiano; Joni K Snyder; Virginia G Wadley; Jennifer Walker; Daniel E Weiner; Paul K Whelton; Valerie M Wilson; Nancy Woolard; Jackson T Wright; Clinton B Wright; Jeff D Williamson; R Nick Bryan Journal: JAMA Date: 2019-08-13 Impact factor: 56.272
Authors: Dae Hyun Kim; Curtis Tatsuoka; Zhengyi Chen; Jackson T Wright; Michelle C Odden; Srinivasan Beddhu; Brandon K Bellows; Adam Bress; Thaddeus Carson; William C Cushman; Karen C Johnson; Donald E Morisky; Henry Punzi; Leonardo Tamariz; Song Yang; Lee-Jen Wei Journal: J Gen Intern Med Date: 2022-08-09 Impact factor: 6.473
Authors: Jodie B Nichols; Michael Malek-Ahmadi; Pierre N Tariot; Geidy E Serrano; Lucia I Sue; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2021-02-22 Impact factor: 3.685